KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:待检查 入排置信度 0.98

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.

Myung-Ju Ahn, Angelo Delmonte, Sharmistha Ghosh, Maximilian Hochmair, Tsung-Ying Yang, James Chih-Hsin Yang, Ji-Youn Han, Karin Holmskov Hansen, Yanyu Wu, Yin Wan, Huamao Mark Lin, Julian Kretz, Bradley Hupf, Ahmet Melih Kurec, Eric N Churchill, Robert J Fram, Citadel Jungco Cabasag, Vishal Goriya, Yuzhe Zhao, Maria Rosario García Campelo

Future Oncol 21(30) 3935-3945

PMID41410381
PMCIDPMC12758242
DOI10.1080/14796694.2025.2592527
发表日期2025-12-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
AI 判定该论文不进入自动 KM 提取:This record is a retrospective chart-review study analyzing outcomes after frontline treatment in the ALTA-1L trial, not a new Phase III RCT. It reports real-world data on subsequent treatments, not the primary Phase III trial results.
摘要

摘要

AIMS: This retrospective, chart-review study evaluated real-world outcomes post-frontline brigatinib in ALTA-1L. METHODS: Patients from ALTA-1L were followed after brigatinib discontinuation. Outcomes evaluated for second-line (2L) treatment included real-world overall response rate (rwORR), time to treatment discontinuation (rwTTD), and progression-free survival (rwPFS). RESULTS: Forty of 48 patients received subsequent systemic anticancer therapies; 30 received 2L ALK tyrosine kinase inhibitors (TKIs), mostly lorlatinib (n = 16) or alectinib (n = 8), and 11 received 2L non-ALK TKI therapy (one with alectinib). rwORR was 33% with 2L ALK TKIs and 0% with 2L non-ALK TKI therapy. Median (95% confidence interval [CI]) 2L rwTTD was 34.7 months (4.6-not reached [NR]) for ALK TKIs (lorlatinib, 37.2 months [6.0-NR]; alectinib, NR [1.1-NR]; crizotinib, 2.8 months [2.0-NR]) and 4.4 months (1.4-6.0) for 2L non-ALK TKI therapy. Median (95% CI) 2L rwPFS was 16.1 months (4.4-NR) with ALK TKIs (lorlatinib, 25.6 months [3.8-NR]; alectinib, 16.1 months [1.1-NR]; crizotinib, 2.4 months [2.0-NR]) and 6.1 months (1.7-NR) with 2L non-ALK TKI therapy. CONCLUSIONS: Following brigatinib discontinuation, most patients initiated a second ALK TKI. Patients treated with 2L second- or third-generation ALK TKIs post-brigatinib experienced prolonged clinical benefit. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT02737501.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。